Anavex Announces Panel Discussion and Presentation at OneMedForum Conference

NEW YORK, NY – January 8, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical stage biopharmaceutical company currently in a Phase 2a clinical trial for Alzheimer’s disease, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will participate in a panel discussion entitled “Neurology and Brain…

Anavex Encouraged by Scientific Data Confirming Sigma-1 Receptor’s Beneficial Direct Interaction with Cannabinoid Receptor

Report Expands Opportunity for Therapeutic Application of Proprietary Anavex Compounds in Neurological Diseases New York — January 6, 2015 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) welcomes new data published in the current issue of the International Journal of Neuropsychopharmacology (IJNP) revealing that the sigma-1 receptor, the Company’s drug target, interacts positively and directly…

Anavex Announces Fiscal 2014 Fourth Quarter and Year-End Financial Results

New York, NY – December 30, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, today reported fourth quarter and year-end results for fiscal year 2014. Upcoming…

Anavex Begins Enrollment of Alzheimer’s Patients in Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS

NEW YORK, NY, December 16, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) today announced enrollment of the first patient in a multicenter Phase 2a clinical trial for ANAVEX 2-73, which is being evaluated for the treatment of Alzheimer’s disease.  The randomized trial is designed to assess the safety and exploratory…

Anavex Upgrades to OTCQX Marketplace

NEW YORK, NY, December 12, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, today announces that the Company is now trading on the OTCQX marketplace under…

Anavex Announces Positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for the Treatment of Alzheimer’s

Data Presented at CNS Summit 2014 Supports Commencement of Phase 2 Clinical Trial in Alzheimer’s Patients NEW YORK, NY, November 17, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) announced full data results from the Phase 1 clinical trial of ANAVEX 2-73, the Company’s lead investigational oral treatment for Alzheimer’s, which…

Anavex to Present Full Phase 1 Clinical Trial Data for ANAVEX 2-73 at CNS Summit 2014 Conference

NEW YORK, NY, November 10, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS), and various types of cancer, is pleased to announce the upcoming presentation of complete Phase 1 clinical trial…

Anavex to Present at SeeThruEquity Investor Conference in New York City

New York, NY – November 6, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, will be featured at the SeeThruEquity Fall Microcap Investor Conference in New…